Work

Bone metabolism biomarkers (BMB) and progression-free survival (PFS) in men with metastatic hormone-sensitive prostate cancer (HSPC): SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) with or without orteronel.

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.5523

Authors: Primo Lara, Edward Mayerson, Erik Gertz, Catherine Tangen, Amir Goldkorn, Marta Van Loan, Maha H. A. Hussain, Shilpa Gupta, Jingsong Zhang, Przemyslaw Twardowski, David I. Quinn, Nicholas J. Vogelzang, Ian Murchie Thompson, Neeraj Agarwal

Institutions: University of California System, United States Department of Agriculture, Western Human Nutrition Research Center, Fred Hutch Cancer Center, University of Southern California, USC Norris Comprehensive Cancer Center, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Cleveland Clinic, Moffitt Cancer Center, City Of Hope National Medical Center, Comprehensive Cancer Centers of Nevada, Christus Santa Rosa Health System, University of Utah, Huntsman Cancer Institute

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Institutes of Health

OpenAlex ID: W3032544747

Cites:

Cited by:

Related to: 10